Top

Published in:

01-04-2018 | Original Article

Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis

Authors: Maria Eduarda Rocha de França, Sura Wanessa Santos Rocha, Wilma Helena Oliveira, Laise Aline Santos, Anne Gabrielle Vasconcelos de Oliveira, Karla Patrícia Sousa Barbosa, Ana Karolina Santana Nunes, Gabriel Barros Rodrigues, Deniele Bezerra Lós, Christina Alves Peixoto

Published in: Inflammopharmacology | Issue 2/2018

Abstract

Background and aim

While diethylcarbamazine citrate (DEC) displays important anti-inflammatory effects in experimental models of liver injury, the mechanisms of its action remain poorly understood. The aim of the present study was to investigate the fibrolytic potential of DEC.

Methods

Mice receive two injections of carbon tetrachloride (CCl₄) per week for 8 weeks. DEC 50 mg/kg body weight was administered through drinking water during the last 12 days of liver injury.

Results

The expression of hepatic stellate cells (HSCs) activation markers, including smooth muscle α-actin (α-SMA), collagen I, transforming growth factor-β 1 (TGF-β1), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) was assessed. The influence of DEC on the intracellular MAPK pathways of the HSCs (JNK and p38 MAPK) was also estimated. DEC inhibited HSCs activation measured as the production of α-SMA and collagen I. In addition, it down regulated the production of TGF-β1 and TIMP-1, and concomitantly increased MMP-2 activity. Furthermore, DEC significantly inhibited the activation of the JNK and p38 MAPK signaling pathways.

Conclusions

In conclusion, DEC significantly attenuated the severity of CCl₄-induced liver injury and the progression of liver fibrosis, exerting a potential fibrolytic effect in the CCl₄-induced fibrosis model.

Akpolat N, Yahsi S, Godekmerdan A et al (2005) The value of α-SMA in the evaluation of hepatic fibrosis severity in hepatitis B infection and cirrhosis development: a histopathological and immunohistochemical study. Histopathology 47:276–280. doi:10.1111/j.1365-2559.2005.02226.x CrossRefPubMed

Bataller R, Brenner D (2005) Science in medicine liver fibrosis. J Clin Invest 115:209–218. doi:10.1172/JCI200524282.The CrossRefPubMedPubMedCentral

Bissell DM, Roulot D, George J (2001) Transforming growth factor beta and the liver. Hepatology 34:859–867. doi:10.1053/jhep.2001.28457 CrossRefPubMed

Bosserhoff A, Hellerbrand C (2011) Obesity and fatty liver are “grease” for the machinery of hepatic fibrosis. Dig Dis 29:377–383. doi:10.1159/000329800 CrossRefPubMed

Carpino G, Morini S, Ginanni Corradini S et al (2005) Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis 37:349–356. doi:10.1016/j.dld.2004.11.009 CrossRefPubMed

Chávez E, Segovia J, Shibayama M et al (2010) Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. Liver Int 30:969–978. doi:10.1111/j.1478-3231.2010.02256.x CrossRefPubMed

Cubero FJ, Urtasun R, Nieto N (2009) Alcohol and liver fibrosis. Semin Liver Dis 29:211–221. doi:10.1055/s-0029-1214376 CrossRefPubMed

Friedman SL (2008a) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88:125–172. doi:10.1152/physrev.00013.2007 CrossRefPubMedPubMedCentral

Friedman SL (2008b) Hepatic fibrosis—overview. Toxicology 254:120–129. doi:10.1016/j.tox.2008.06.013 CrossRefPubMed

Friedman SL, Sheppard D, Duffield JS, Violette S (2013) Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 5:167sr1. doi:10.1126/scitranslmed.3004700 CrossRefPubMed

Gonzalez R, Ancheta O, Marquez M, Rodriguez S (1994) Hepatoprotective effects of diethylcarbamazine in acute liver damage induced by carbon tetrachloride in rats. Acta Pharmacol Sin 15:495–497

Gressner OA, Gao CA (2014) Monitoring fibrogenic progression in the liver. Clin Chim Acta 433:111–122. doi:10.1016/j.cca.2014.02.021 CrossRefPubMed

Gressner AM, Weiskirchen R, Breitkopf K, Dooley S (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7:d793–d807. doi:10.2741/gressner CrossRefPubMed

Hemmann S, Graf J, Roderfeld M, Roeb E (2007) Expression of MMPs and TIMPs in liver fibrosis—a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46:955–975. doi:10.1016/j.jhep.2007.02.003 CrossRefPubMed

Hewitt RI (1947) Experimental chemotherapy of filariasis; effect of piperazine derivatives against naturally acquired filarial infections in cotton rats and dogs. J Lab Clin Med 32:1304–1313PubMed

Hong IH, Park SJ, Goo MJ et al (2013) JNK1 and JNK2 regulate α-SMA in hepatic stellate cells during CCl4-induced fibrosis in the rat liver. Pathol Int 63:483–491. doi:10.1111/pin.12094 CrossRefPubMed

Iredale JP (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117:539–548. doi:10.1172/JCI30542 CrossRefPubMedPubMedCentral

Jarčuška P, Janičko M, Veselíny E et al (2010) Circulating markers of liver fibrosis progression. Clin Chim Acta 411:1009–1017. doi:10.1016/j.cca.2010.04.009 CrossRefPubMed

Johnson GL, Johnson GL, Lapadat R, Lapadat R (2002) Mitogen-activated protein kinase pathways Mediated by ERK, JNK, and p38 protein kinases. Science (80-) 298:1911–1912CrossRef

Kluwe J, Pradere JP, Gwak GY et al (2010) Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138:347–359. doi:10.1053/j.gastro.2009.09.015 CrossRefPubMed

Kong X, Horiguchi N, Mori M, Gao B (2012) Cytokines and STATs in liver fibrosis. Front Physiol 3:69. doi:10.3389/fphys.2012.00069 CrossRefPubMedPubMedCentral

Kweon Y, Kweon Y, Goodman ZD et al (2001) Decreasing brogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Clin Invest 35:749–755

Lee UE, Friedman SL (2011) Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25:195–206. doi:10.1016/j.bpg.2011.02.005 CrossRefPubMedPubMedCentral

Leung T-M, Fung M-L, Liong EC et al (2011) Role of nitric oxide in the regulation of fibrogenic factors in experimental liver fibrosis in mice. Histol Histopathol 26:201–211PubMed

Lin X, Zhang S, Huang Q et al (2012) Protective effect of Fufang–Liu–Yue–Qing, a traditional Chinese herbal formula, on CCl₄ induced liver fibrosis in rats. J Ethnopharmacol 142:548–556. doi:10.1016/j.jep.2012.05.040 CrossRefPubMed

Maizels RM, Denham DA (1992) Diethilcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug. Parasitology 105:849–860CrossRef

McCrudden R, Iredale JP (2000) Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 15:1159–1168PubMed

Mohammed FF, Pennington CJ, Kassiri Z et al (2005) Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 41:857–867. doi:10.1002/hep.20618 CrossRefPubMed

Mormone E, George J, Nieto N (2011) Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 193:225–231. doi:10.1016/j.cbi.2011.07.001 CrossRefPubMedPubMedCentral

Parsons CJ, Bradford BU, Pan CQ et al (2004) Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40:1106–1115. doi:10.1002/hep.20425 CrossRefPubMed

Peixoto CA, Silva BS (2014) Anti-inflammatory effects of diethylcarbamazine: a review. Eur J Pharmacol 734C:35–41. doi:10.1016/j.ejphar.2014.03.046 CrossRef

Probst A, Dang T, Bochud M et al (2011) Role of Hepatitis C virus genotype 3 in liver fibrosis progression—a systematic review and meta-analysis. J Viral Hepat 18:745–759. doi:10.1111/j.1365-2893.2011.01481.x CrossRefPubMed

Raman M, Chen W, Cobb MH (2007) Differential regulation and properties of MAPKs. Oncogene 26:3100–3112. doi:10.1038/sj.onc.1210392 CrossRefPubMed

Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180–186. doi:10.1016/S0955-0674(97)80061-0 CrossRefPubMed

Rocha SWS, De França MER, Rodrigues GB et al (2014) Diethylcarbamazine reduces chronic inflammation and fibrosis in carbon tetrachloride-(CCl₄-) induced liver injury in mice. Mediators Inflamm 2014:1–15. doi:10.1155/2014/696383 CrossRef

Rodrigues GB, Rocha SWS, Dos Santos LAM et al (2015) Diethylcarbamazine: possible therapeutic alternative in the treatment of alcoholic liver disease in C57BL/6 mice. Clin Exp Pharmacol Physiol 42:369–379. doi:10.1111/1440-1681.12369 CrossRefPubMed

Santos Rocha SW, Oliveira Dos Santos AC, Dos Santos Silva B et al (2012a) Effects of diethylcarbamazine (DEC) on hepatocytes of C57BL/6 J mice submitted to protein malnutrition. J Food Drug Anal 20:524–531

Santos Rocha SW, Santos Silva B, Dos Santos Gomes FO et al (2012b) Effect of diethylcarbamazine on chronic hepatic inflammation induced by alcohol in C57BL/6 mice. Eur J Pharmacol 689:194–203. doi:10.1016/j.ejphar.2012.05.044 CrossRefPubMed

Sapkota GP (2013) The TGFβ-induced phosphorylation and activation of p38 mitogen-activated protein kinase is mediated by MAP3K4 and MAP3K10 but not TAK1. Open Biol 3:130067. doi:10.1098/rsob.130067 CrossRefPubMedPubMedCentral

Schuppan D, Kim YO (2013) Review series evolving therapies for liver fi brosis. 123:1887–1901. doi:10.1172/JCI66028.The

Schuppan D, Ruehl M, Somasundaram R, Hahn EG (2001) Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21:351–372. doi:10.1055/s-2001-17556 CrossRefPubMed

Seki E, de Minicis S, Inokuchi S et al (2009) CCR2 promotes hepatic fibrosis in mice. Hepatology 50:185–197. doi:10.1002/hep.22952 CrossRefPubMedPubMedCentral

Terpstra A (2001) Differences between humans and mice in efficacy of the body fat lowering effect of conjugated linoleic acid: role of metabolic rate. J Nutr 131:2067–2068CrossRefPubMed

Tock J, Van Putten V, Stenmark KR, Nemenoff RA (2003) Induction of SM-α-actin expression by mechanical strain in adult vascular smooth muscle cells is mediated through activation of JNK and p38 MAP kinase. Biochem Biophys Res Commun 301:1116–1121. doi:10.1016/S0006-291X(03)00087-1 CrossRefPubMed

Tsukada S, Parsons CJ, Rippe RA (2006) Mechanisms of liver fibrosis. Clin Chim Acta 364:33–60. doi:10.1016/j.cca.2005.06.014 CrossRefPubMed

Xu R, Zhang Z, Wang F-S (2012) Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol 9:296–301. doi:10.1038/cmi.2011.53 CrossRefPubMed

Xu J, Liu X, Koyama Y et al (2014) The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol 5:1–12. doi:10.3389/fphar.2014.00167

Yao Q, Lin Y, Li X et al (2013) Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis. Toxicol Lett 222:72–82. doi:10.1016/j.toxlet.2013.06.240 CrossRefPubMed

Yata Y, Gotwals P, Koteliansky V, Rockey DC (2002) Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 35:1022–1030. doi:10.1053/jhep.2002.32673 CrossRefPubMed

Yoshiji H, Kuriyama S, Yoshii J et al (2002) Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36:850–860. doi:10.1016/S0270-9139(02)00091-5 CrossRefPubMed

Zhang YE (2009) Non-Smad pathways in TGF-β signaling. Cell Res 19:128–139. doi:10.1038/cr.2008.328.Non-Smad CrossRefPubMedPubMedCentral

Zhao L (2003) Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 107:234–237. doi:10.1161/01.CIR.0000050653.10758.6B CrossRefPubMed

Title: Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis
Authors: Maria Eduarda Rocha de França
Sura Wanessa Santos Rocha
Wilma Helena Oliveira
Laise Aline Santos
Anne Gabrielle Vasconcelos de Oliveira
Karla Patrícia Sousa Barbosa
Ana Karolina Santana Nunes
Gabriel Barros Rodrigues
Deniele Bezerra Lós
Christina Alves Peixoto
Publication date: 01-04-2018
Publisher: Springer International Publishing
Published in: Inflammopharmacology / Issue 2/2018
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-017-0329-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis

Abstract

Background and aim

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Precancerous ACF induction affects their regional distribution forsaking oxidative stress implication in 1,2-dimethylhydrazine-induced colon carcinogenesis model

Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations

Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor

Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson’s disease model

Anti-inflammatory evaluation and characterization of leaf extract of Ananas comosus

Terminalia arjuna prevents Interleukin-18-induced atherosclerosis via modulation of NF-κB/PPAR-γ-mediated pathway in Apo E−/− mice